Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$13.70 USD
+0.08 (0.59%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $13.69 -0.01 (-0.07%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CATX 13.70 +0.08(0.59%)
Will CATX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CATX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CATX
Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet
PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth
CATX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates
Other News for CATX
Perspective Therapeutics initiated with bullish view at BofA, here's why
3 Outperforming Stocks Surpassing Even Nvidia This Year
BofA starts Perspective at buy, cites use of radioactive Lead-212
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results
Buy Rating Maintained for Perspective Therapeutics Amidst Positive Long-Term Growth Prospects and Upcoming Clinical Catalysts